Key Takeaways The FDA review and potential success of Anaphylm could drive strong revenue growth and shift market preference toward needle-free drug delivery. Strategic investments in awareness, payer access, and product pipeline position the company for rapid adoption, diversified revenue, and improved margins.
Key Takeaways Accelerated global expansion and unique patient-first strategies could drive faster uptake and broader revenue diversification for Anaphylm than analysts currently anticipate. Oral film technology and scalable PharmFilm portfolio position the company for sustained leadership, margin expansion, and strong long-term earnings leverage as care models evolve.
Key Takeaways Barriers like access restrictions, payer dynamics, and education needs may limit rapid revenue growth despite the promise of innovative oral drug delivery products. Dependence on a few high-risk assets and heavy financing requirements expose the company to market share, profitability, and shareholder value risks.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
